Sign up Australia
Proactive Investors - Run By Investors For Investors

M Pharmaceutical expecting very big things of C-103 and Extrinsa

One's a weight loss drug, the other deals with female sexual desire disorder. The potential market sizes for both are absolutely enormous.
Female sexual disorder
M anticipates Extrinsa will be extremely well tolerated and highly effective for a large number of women suffering from female sexual disorders

Having reduced the unwanted side-effects of weight loss drug Orlistat, M Pharmaceutical Inc (CNSX:MQ) is targeting US$500mln annual US revenues from its new formulation.

Orlistat blocks some of the fat that is consumed by users, keeping it from being absorbed by your body.

Once an US$800mln a year drug..

It was once an US$800mln a year drug, before socially unacceptable side effects - let’s just say it was advisable to have a change of underwear and an air freshener to hand when taking the drug - caused its popularity to wane.

M thinks it has cracked those unwanted side effects, and should the drug receive approval from the US Food and Drug Administration (FDA), its number crunchers came up with the US$500mln a year revenue projection - and that’s just based on the first year it goes on sale.

The projections were based on conservative patient prescription figures at a US$125 wholesale cost and adjustments for population growth and obesity rate growth.

The total estimated patient market (ages 17 to 65, with an obesity rate of 37.9%) is 83.38 million in 2017 compared with 58,633,200 in 2000, when the drug was launched with the Xenical brand name.

The opportunity for M is obviously enormous, but it did caution that substantial funds would be required for development costs, though these would be lower than the sort of money needed to develop a drug from scratch.

READ M Pharmaceutical shares surge as the drug developer outlines exciting future

WATCH M Pharma's Gary Thompson 'excited' to receive US Extrinsa trademark

Meanwhile, the company has also been “bigging up” the market opportunity for Extrinsa, a form of the prescription drug tadalafil - the infamous Cialis mentioned in so many spam emails - that is applied to the skin.

M Pharma is targeting Extrinsa at the female market, primarily as a treatment for sexual arousal disorder with the possibility of it also working as a remedy for women unable to obtain orgasm.

M reckons this is a US$1bn opportunity..

M reckons this is a US$1bn opportunity; Addyi, the only drug currently approved for the treatment of female sexual desire disorder was purchased by Valeant Pharmaceuticals Intl Inc (NYSE:VRX) from Sprout for more than $1-billion in 2016.

Valeant had estimated that sales would ramp up to US$1-billion annually for this drug, and it makes no claims to treat orgasm disorders, so the potential market for Extrinsa should be higher still.

“The Extrinsa treatment is topical, local and non-systemic, with daily and on demand use, while being non-hormonal and not a central nervous system drug. Based on these core attributes, the safety profiles of the API and excipients in the drug product, and the dosage and delivery form, the company anticipates Extrinsa to be extremely well tolerated and highly effective for a large number of women suffering from female sexual disorders and has a great likelihood of approval by the FDA,” M Pharma said.

As with C-103, its reformulation of Orlistat, Extrinsa will require substantial funds for development.

View full LILY profile View Profile

Callitas Health Inc. Timeline

Related Articles

March 19 2018
The group has received key permits to allow cannabis - flowers and oils - to be imported into Australia from Aurora Cannabis Inc
test tubes in a laboratory
November 06 2017
“We are delighted that RedX has exited administration as a going concern and with a strengthened board and management team that will ensure enhanced oversight and provide relevant industry expertise as well as continuity to the business”
cancer cell
February 01 2018
The highlights included successful US and European ovarian cancer studies that underlined the potential of the company’s Parsortix liquid biopsy system

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use